WuXi Biologics Breaks Ground on CRDMO Center in Singapore

March 22, 2024  Source: drugdu 188

"/Singapore, March 19, 2024, WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore. The center will provide integrated biologics research, development and manufacturing services.

WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to WuXi Biologics' global network, and is expected to employ 1,500 staff.

The site will be equipped with WuXi Biologics' proprietary technical platforms, along with industry-leading technologies such as single-use technology to provide clients with time-and cost-efficient services. In line with WuXi Biologics' Environmental, Social and Governance strategy, the site will implement sustainable concepts in the design and construction of the center, deploy digital tools and build energy-saving facilities.

Mr. Png Cheong Boon, Chairman of EDB, said that WuXi Biologics Singapore CRDMO center will strengthen Singapore's biopharmaceutical sector, which comprises global healthcare companies operating best-in-class manufacturing and R&D facilities, complemented by a strong local R&D and start-up ecosystem. This investment will create significant employment opportunities for Singaporeans, and spur collaborations between WuXi Biologics, our R&D institutions and startups to develop innovative therapeutics and novel modalities. Singapore continues to welcome global healthcare players seeking to innovate, manufacture and commercialize end-to-end solutions for clients worldwide.

https://mp.weixin.qq.com/s?__biz=MzIxOTEyMTI1Nw==&mid=2651329404&idx=1&sn=5f59884f7dced03bebce0a7b2602df9a&chksm=8c1ca07abb6b296cadbbd69c5917ea509b963038cb87a0d4373890f5931922273e90454079a7&mpshare=1&scene=1&srcid=0319hu9ruqjMd5MTiYNhPhlu&sharer_shareinfo=96c814a60f046359cf909dd5116db6a3&sharer_shareinfo_first=96c814a60f046359cf909dd5116db6a3#rd

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.